ClinicalTrials.gg
Status unknownNCT02598245URGE-IIIUpdated Nov 5, 2015

Comparison of TOT 8/4 Versus TOT 6/3

An interventional study of TOT 8/4 and TOT 6/3 in Urinary Incontinence, sponsored by Klinikum der Universität Köln. Status unknown at 1 site in Germany. Open to female participants. Per ClinicalTrials.gov, last updated 2015-11-05.

Sponsored by Klinikum der Universität Köln · Not applicable and Interventional

The sponsor has not verified this record recently (last verified Nov 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Sex
Female
01

Study summary

Transobturator tapes (TOT) are placed according to the surgical technique described by Delorme et al. in patients with a previous cervico-sacropexy (CESA) or vagino-sacropexy (VASA). Before final Fixation of the tapes and suturing the vaginal skin a Hegar dilator sound with either 8 mm or 6 mm diameter is placed in the urethra and a second Hegar dilator sound with either 4 mm or 3 mm diameter is placed between the tape and the urethra. After suturing the vaginal skin the Hegar sounds are removed.

Read the detailed description

Retrospective studies demonstrated that the distance between urethra and suburethral sling can vary considerably between 1 mm and 10 mm. In order to standardize the placement of the suburethral sling we choose two different distances between urethra and sling.

Transobturator tape (TOT) are placed according to the surgical technique described by Delorme et al. in patients with a previous cervico-sacropexy (CESA) or vagino-sacropexy (VASA). Before final fixation of the sling and suturing the vaginal skin a Hegar dilator sound with either 8 mm or 6 mm diameter is placed in the urethra and a second Hegar dilator sound with either 4 mm or 3 mm diameter is placed between the tape and the urethra. After suturing the vaginal skin the Hegar sounds are removed.

According to the used Hegar dilator sounds two different techniques are used:

TOT 8/4 or TOT 6/3.

02

Conditions studied

  • Urinary Incontinence

Keywords

  • urinary incontinence, CESA, VASA, TOT, TVT
03

In context

Urinary Incontinence

1,375 studies on the registry are indexed under Urinary Incontinence; 224 are open to participants now.

This study's planned enrollment of 120 is above the median of 66 across 1,021 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Klinikum der Universität Köln is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • urinary incontinence

Exclusion criteria

Exclusion Criteria:

  • previous TOT or TVT
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    TOT 8/4

    Transobturator sling (TOT) is placed according to the original description. Instead of a "Metzenbaum Scissor" which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin.

    Device: TOT 8/4

  • Experimental
    TOT 6/3

    Transobturator sling (TOT) is placed according to the original description. Instead of a "Metzenbaum Scissor" which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin.

    Device: TOT 6/3

Interventions

  • DeviceTOT 8/4

    placement of transobturator sling according to the TOT 8/4 technique

  • DeviceTOT 6/3

    placement of transobturator sling according to the TOT 6/3 technique

06

What researchers measure

Primary outcomes

  1. Distance between urethra and transobturator sling

    transvaginal ultrasound measurements

    Time frame: 2 weeks

Secondary outcomes

  1. Distance between urethra and transobturator sling

    transvaginal ultrasound measurements

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Obstetrics and Gynecology, University of Cologne
    Cologne, North Rhine-Westphalia 50931, Germany
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02598245
Lead sponsor
Klinikum der Universität Köln
Responsible party
Professor Dr. Wolfram Jäger (Professor, Klinikum der Universität Köln) — Principal investigator
First posted
Nov 5, 2015
Start date
Jan 2015
Primary completion
Dec 2018 (estimated)
Completion
Apr 2019 (estimated)
Last update
Nov 5, 2015

Study contacts

Sebastian Ludwig, MD
Contact
sebastian.ludwig@uk-koeln.de
+49 221 478 ext. 97303
Wolfram Jager, Professor
Contact
wolfram.jaeger@uk-koeln.de
+49 221 478 ext. 97030
Wolfram Jager, Professor
study director · Head of the Department of Urogyne

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion